Opticyte Inc. develops next-generation oximetry technology. This technology allows clinicians real-time monitoring of cellular oxygenation and perfusion. Early detection and intervention for shock improves patient outcomes and reduces healthcare costs in ICUs, ORs, and EDs. The firm's CellSat™ oximetry technology has been refined in the Schenkman Laboratory at the University of Washington. The technology has made significant strides toward de-risking the measurement of myoglobin oxygenation in superficial skeletal muscle and the use of that measurement in the emergency department.
